UK MHRA Authorizes Arrowhead’s REDEMPLO for FCS
REDEMPLO (plozasiran) received MHRA marketing authorization as an adjunct to diet to reduce triglycerides. NICE also backed NHS funding in England and Wales.
Related stories
India Regulator Recommends Ending Capital Gains Tax for Foreign Investors
India’s markets regulator has recommended that the government remove the long-term capital gains tax imposed on foreign investors, according to two people with direct knowledge of
L impact | REGULATION | Nov 02, 2026, 10:05 AM UTC
Singapore Orders Independent Review of Golden Agri Subsidiary
Singapore’s environment agency ordered an independent review of a Golden Agri subsidiary over transboundary air pollution.
L impact | REGULATION | Nov 02, 2026, 09:46 AM UTC
Gencurix Trading Halt Extended Pending Delisting Review Decision
Trading in Gencurix common shares on the KOSDAQ has been extended until a decision is made on whether grounds for delisting apply.
L impact | REGULATION | Nov 02, 2026, 09:34 AM UTC
Handal Energy Faces Bursa Delisting Over Overdue 2025 Annual Report
Handal Energy faces potential delisting from Bursa over its overdue 2025 annual report.
M impact | REGULATION | Nov 02, 2026, 09:25 AM UTC
Belgian Prime Minister Bart De Wever Submits Resignation to King
Reuters reports that Belgian Prime Minister Bart De Wever submitted his resignation to the king.
M impact | REGULATION | Nov 02, 2026, 09:23 AM UTC
FDA Approves Inovio Treatment; Shares More Than Triple Premarket
The FDA approved an Inovio treatment for a rare respiratory condition. Inovio shares more than tripled premarket.
M impact | REGULATION | Nov 02, 2026, 09:14 AM UTC